Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry

Trial Profile

Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Nifurtimox (Primary)
  • Indications Chagas disease
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 06 Jun 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 06 Jun 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
    • 25 Mar 2014 Planned End Date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top